BAM
EBS icon

Bellevue Asset Management’s Emergent Biosolutions EBS Stock Holding History

Bellevue Asset Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-44
Closed -$4K – 605
2021
Q1 		$4K Sell
44
-5
-10% -$512 ﹤0.01% 455
2020
Q4 		$5K Buy
49
+8
+20% +$734 ﹤0.01% 415
2020
Q3 		$4K Hold
41
– – ﹤0.01% 419
2020
Q2 		$3K Hold
41
– – ﹤0.01% 470
2020
Q1 		$3K Buy
41
+24
+141% +$1.38K ﹤0.01% 446
2019
Q4 		$1K Buy
+17
New +$922 ﹤0.01% 488

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Asset Management's EBS Position: Q2 2021 in Review

Bellevue Asset Management sold out of Emergent Biosolutions (EBS) in Q2 2021, closing a stake of 44 shares — an estimated $4K sold.

Bellevue Asset Management first reported a position in EBS in Q4 2019 and held it in 6 quarters. The position peaked at $5K in Q4 2020. 290 funds tracked by Wall St. Rank hold EBS as of Q2 2021.

  • Bellevue Asset Management reported no remaining Emergent Biosolutions position as of Q2 2021 after selling out during the quarter.
  • Bellevue Asset Management sold 44 Emergent Biosolutions shares in Q2 2021, an estimated $4K.
  • Bellevue Asset Management first reported a position in Emergent Biosolutions in Q4 2019 and held it in 6 quarters.
  • Bellevue Asset Management's Emergent Biosolutions position peaked at $5K in Q4 2020.
  • 290 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2021.

Based on Bellevue Asset Management's 13F filing for Q2 2021, filed 9 Aug 2021.